Evidence map›Paper›PMID 40170846›Full record

ArticleFrontiers in immunology2025

Effects of two different variants in the

Lucía Del Pino Molina, Elena Monzón Manzano, Carla Gianelli, Luz Yadira Bravo Gallego, Javier Bujalance Fernández, Paula Acuña, Yolanda Soto Serrano, Keren Reche Yebra, María Bravo García-Morato, Elena Sánchez Zapardiel and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lucía Del Pino Molina *Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain.
Elena Monzón Manzano *Hematology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Carla GianelliLymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Luz Yadira Bravo GallegoCenter for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain.
Javier Bujalance FernándezLymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Paula AcuñaHematology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Yolanda Soto SerranoLymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Keren Reche YebraLymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
María Bravo García-MoratoCenter for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain.
Elena Sánchez ZapardielLymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Elena G Arias-SalgadoHematology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Rebeca Rodríguez PenaCenter for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain.
Nora ButtaHematology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Eduardo López GranadosCenter for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection and neoplasia (XMEN) disease is caused by hemizygous loss of function (LOF) gene variants in Methods: We performed a functional validation of these two variants in the Results: We analyzed the B-cell compartment, we found that the B-cell expansion is driven by immature/transitional (CD5 Discussion: Here, we report the two different outcomes regarding EBV-driven lymphoproliferative complications, the family with three members affected that developed the malignant lymphoproliferative complications before XMEN diagnosis, and the patient with early diagnose of MAGT1 deficiency due to EBV viremia. As a recommendation, XMEN disease should be ruled out in males with impaired clearance of EBV-infection and EBV-driven lymphoproliferative complications.

Indexed as

Blood PlateletsB-Lymphocyte SubsetsEpstein-Barr Virus InfectionsMembrane Transport ProteinsX-Linked Combined Immunodeficiency DiseasesAdultCation Transport ProteinsFemaleHerpesvirus 4, HumanHumansMalePedigreeCation Transport ProteinsMagT1 protein, humanMembrane Transport ProteinsB cell phenotypecalcium influxglycosylationMAGT1plateletsXMEN

Identifiers

PMID40170846
PMCPMC11958192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.